Results 151 to 160 of about 1,126,910 (189)

The use of cyclooxygenase-2 inhibitors for improvement of efficacy of radiotherapy in cancers.

Drug Discovery Today, 2016
E. Salehifar, S. Hosseinimehr
semanticscholar   +1 more source

Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed.

European Journal of Pharmacology, 2015
R. Liu, Kang-ping Xu, Guishan Tan
semanticscholar   +1 more source

The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies

Expert Opinion on Drug Discovery, 2014
M. Vosooghi, M. Amini
semanticscholar   +1 more source

Selective Cyclooxygenase-2 Inhibitors

2004
Publisher Summary Cyclooxygenase (prostaglandin G/H synthase) catalyzes the conversion of arachidonic acid (AA) into prostaglandin H2 as the first committed step of prostaglandin biosynthesis. This enzyme is known to be the target of acetyl salicylic acid (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs).
openaire   +1 more source

Perioperative administration of selective cyclooxygenase-2 inhibitors for postoperative pain management in patients after total knee arthroplasty.

Journal of Arthroplasty, 2013
Jun Lin, Lei Zhang, Huilin Yang
semanticscholar   +1 more source

Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.

Biochemical Pharmacology, 2002
D. Mukherjee
semanticscholar   +1 more source

Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.

Archives of Internal Medicine, 2000
D. Watson, S. Harper, P. Zhao, H. Quan, J. Bolognese, T. Simon   +5 more
semanticscholar   +1 more source

Aromatase inhibitors and cyclooxygenase-2 (COX-2) inhibitors in endometriosis: new questions--old answers?

European Journal of Obstetrics, Gynecology, and Reproductive Biology, 2005
A. Ebert, J. Bartley, M. David
semanticscholar   +1 more source

3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors.

Bioorganic & Medicinal Chemistry Letters, 2004
R. Ranatunge, R. Earl, D. Garvey, D. Janero, L. Letts, Allison M. Martino, Madhavi G. Murty, S. Richardson, David J. Schwalb, D. Young, Irina S. Zemtseva   +10 more
semanticscholar   +1 more source

The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life.

Bioorganic & Medicinal Chemistry Letters, 2010
Jane L. Wang, David C. Limburg, M. Graneto, J. Springer, Joseph Rogier Bruce Hamper, S. Liao, J. Pawlitz, R. Kurumbail, T. Maziasz, J. Talley, J. Kiefer, J. Carter   +11 more
semanticscholar   +1 more source